Consistently, the wound migration test showed that CM from CAFsnPM or CAFsPM accelerated the cell migration and invasion ability of HCT116 and DLD1 cells, but CM from CAFsPM treated with ETO significantly reduced the migration of CRC cells (Fig. 4B; Fig. S5). The gene discussed is RUNX1T1; the disease is colorectal carcinoma.